致癌性Ras诱导的IL6分泌是肿瘤发生所必需的。
Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis.
作者信息
Ancrile Brooke, Lim Kian-Huat, Counter Christopher M
机构信息
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA.
出版信息
Genes Dev. 2007 Jul 15;21(14):1714-9. doi: 10.1101/gad.1549407.
Abstract
Ras is mutated to remain in the active oncogenic state in many cancers. As Ras has proven difficult to target therapeutically, we searched for secreted, druggable proteins induced by Ras that are required for tumorigenesis. We found that Ras induces the secretion of cytokine IL6 in different cell types, and that knockdown of IL6, genetic ablation of the IL6 gene, or treatment with a neutralizing IL6 antibody retard Ras-driven tumorigenesis. IL6 appears to act in a paracrine fashion to promote angiogenesis and tumor growth. Inhibiting IL6 may therefore have therapeutic utility for treatment of cancers characterized by oncogenic Ras mutations.
摘要
在许多癌症中，Ras发生突变并维持在致癌活性状态。由于已证明Ras难以成为治疗靶点，我们寻找由Ras诱导分泌的、可成药的、肿瘤发生所必需的蛋白质。我们发现，Ras在不同细胞类型中诱导细胞因子IL6的分泌，并且敲低IL6、对IL6基因进行基因敲除或用中和性IL6抗体处理可延缓Ras驱动的肿瘤发生。IL6似乎以旁分泌方式发挥作用，促进血管生成和肿瘤生长。因此，抑制IL6可能对治疗以致癌Ras突变为特征的癌症具有治疗作用。
相似文献
1
Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis.致癌性Ras诱导的IL6分泌是肿瘤发生所必需的。
Genes Dev. 2007 Jul 15;21(14):1714-9. doi: 10.1101/gad.1549407.
2
ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis.E 选择素配体阳性 CXC 趋化因子与致癌性 Ras 介导的肿瘤发生
Carcinogenesis. 2009 Nov;30(11):1841-7. doi: 10.1093/carcin/bgp198. Epub 2009 Oct 5.
3
Oncogenic potential of BRAF versus RAS.BRAF与RAS的致癌潜力
Cancer Lett. 2008 Mar 18;261(2):137-46. doi: 10.1016/j.canlet.2007.10.033. Epub 2008 Feb 14.
4
Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice.反义DNA对裸鼠中由c-Ha-ras癌基因诱导的肿瘤生长的抑制作用。
Cancer Res. 1993 Feb 1;53(3):577-80.
5
Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis.Sprouty-2在肺发育和肿瘤发生过程中调控致癌性K-ras。
Genes Dev. 2007 Mar 15;21(6):694-707. doi: 10.1101/gad.1526207.
6
IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis.IL6 转信号促进 KRAS 驱动的肺癌发生。
Cancer Res. 2016 Feb 15;76(4):866-76. doi: 10.1158/0008-5472.CAN-15-2388. Epub 2016 Jan 7.
7
Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.表达KRAS C118S的细胞系中HRAS G12V驱动的肿瘤发生减少。
PLoS One. 2015 Apr 22;10(4):e0123918. doi: 10.1371/journal.pone.0123918. eCollection 2015.
8
Oncogenic ras fails to restore an in vivo tumorigenic phenotype in embryonic stem cells lacking vascular endothelial growth factor (VEGF).致癌性Ras无法在缺乏血管内皮生长因子（VEGF）的胚胎干细胞中恢复体内致瘤表型。
Biochem Biophys Res Commun. 1999 Jan 19;254(2):480-3. doi: 10.1006/bbrc.1998.9966.
9
Growth differentiation factor-15 upregulates interleukin-6 to promote tumorigenesis of prostate carcinoma PC-3 cells.生长分化因子 15 通过上调白细胞介素 6 促进前列腺癌细胞 PC-3 的肿瘤发生。
J Mol Endocrinol. 2012 Sep 5;49(2):153-63. doi: 10.1530/JME-11-0149. Print 2012 Oct.
10
Autocrine activity of interleukin 6 secreted by hepatocarcinoma cell lines.肝癌细胞系分泌的白细胞介素6的自分泌活性。
Mol Biol Med. 1991 Feb;8(1):141-56.
引用本文的文献
1
Exploring the genetic alterations of Gorham-Stout disease.探索戈勒姆-斯托特病的基因改变。
Front Endocrinol (Lausanne). 2025 Aug 19;16:1654497. doi: 10.3389/fendo.2025.1654497. eCollection 2025.
2
Targeting Senescence in Oncology: An Emerging Therapeutic Avenue for Cancer.肿瘤学中的衰老靶向治疗：癌症治疗的新兴途径
Curr Oncol. 2025 Aug 18;32(8):467. doi: 10.3390/curroncol32080467.
3
Structure-Based Design of Small-Molecule Inhibitors of Human Interleukin-6.基于结构的人白细胞介素-6小分子抑制剂设计
Molecules. 2025 Jul 10;30(14):2919. doi: 10.3390/molecules30142919.
4
Cellular senescence and other age-related mechanisms in skeletal diseases.骨骼疾病中的细胞衰老及其他与年龄相关的机制。
Bone Res. 2025 Jul 7;13(1):68. doi: 10.1038/s41413-025-00448-7.
5
Role of Cellular Senescence in Parkinson's Disease: Potential for Disease-Modification Through Senotherapy.细胞衰老在帕金森病中的作用：通过衰老疗法进行疾病修饰的潜力。
Biomedicines. 2025 Jun 7;13(6):1400. doi: 10.3390/biomedicines13061400.
6
Elucidating Ras protein as a dual therapeutic target for inflammation and cancer: a review.阐明Ras蛋白作为炎症和癌症的双重治疗靶点：综述
Discov Oncol. 2025 Jun 7;16(1):1029. doi: 10.1007/s12672-025-02783-x.
7
Bidirectional regulation of the cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon gene pathway and its impact on hepatocellular carcinoma.环磷酸鸟苷-磷酸腺苷合酶-干扰素基因刺激因子通路的双向调控及其对肝细胞癌的影响
World J Gastrointest Oncol. 2025 Feb 15;17(2):98556. doi: 10.4251/wjgo.v17.i2.98556.
8
Oncogenic RAS in Cancers from the DNA Replication Stress and Senescence Perspective.从DNA复制应激和衰老角度看癌症中的致癌RAS
Cancers (Basel). 2024 Nov 28;16(23):3993. doi: 10.3390/cancers16233993.
9
PIM1 kinase and its diverse substrate in solid tumors.PIM1 激酶及其在实体瘤中的多种底物。
Cell Commun Signal. 2024 Nov 1;22(1):529. doi: 10.1186/s12964-024-01898-y.
10
Nasopharyngeal carcinoma-associated inflammatory cytokines: ongoing biomarkers.鼻咽癌相关炎症细胞因子：正在研究的生物标志物。
Front Immunol. 2024 Oct 17;15:1448012. doi: 10.3389/fimmu.2024.1448012. eCollection 2024.
本文引用的文献
1
Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells.RalA和RalB在人胰腺癌细胞恶性生长中的不同作用。
Curr Biol. 2006 Dec 19;16(24):2385-94. doi: 10.1016/j.cub.2006.10.023.
2
A genetically defined normal human somatic cell system to study ras oncogenesis in vivo and in vitro.一种用于在体内和体外研究ras致癌作用的基因定义的正常人类体细胞系统。
Methods Enzymol. 2006;407:637-47. doi: 10.1016/S0076-6879(05)07050-3.
3
Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.使用抗白细胞介素-6单克隆抗体CNTO328抑制白细胞介素-6，可抑制去势小鼠中雄激素依赖性前列腺癌向雄激素非依赖性表型的转变。
Cancer Res. 2006 Mar 15;66(6):3087-95. doi: 10.1158/0008-5472.CAN-05-3447.
4
Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine.人卵巢癌细胞分泌的白细胞介素-6是一种强效促血管生成细胞因子。
Cancer Res. 2005 Dec 1;65(23):10794-800. doi: 10.1158/0008-5472.CAN-05-0623.
5
Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance.肿瘤维持过程中致癌性Ras信号传导对PI3K/AKT途径激活的需求降低。
Cancer Cell. 2005 Nov;8(5):381-92. doi: 10.1016/j.ccr.2005.10.014.
6
Monoclonal antibody therapy of cancer.癌症的单克隆抗体疗法。
Nat Biotechnol. 2005 Sep;23(9):1147-57. doi: 10.1038/nbt1137.
7
Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1.白细胞介素-6在体内诱导星形胶质细胞中血管内皮生长因子（VEGF）的转录激活，并通过信号转导和转录激活因子3（STAT3）与特异性蛋白1（Sp1）之间的直接相互作用调节胶质母细胞瘤细胞中的VEGF启动子活性。
Int J Cancer. 2005 Jun 10;115(2):202-13. doi: 10.1002/ijc.20871.
8
Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis.Ras诱导的白细胞介素-8表达在肿瘤生长和血管生成中起关键作用。
Cancer Cell. 2004 Nov;6(5):447-58. doi: 10.1016/j.ccr.2004.09.028.
9
Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis.胰腺癌中的细胞因子：与表型特征及预后的相关性
Cancer. 2004 Dec 15;101(12):2727-36. doi: 10.1002/cncr.20672.
10
Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma.白细胞介素-6增加胃癌中血管内皮生长因子水平并促进血管生成。
J Biomed Sci. 2004 Jul-Aug;11(4):517-27. doi: 10.1007/BF02256101.
Zotero 插件